Il1f10 Antibody

What is IL1F10 and what is its biological significance?

IL1F10 is a novel member of the interleukin-1 (IL-1) gene family located on human chromosome 2q13-14.1 near the IL-1 receptor antagonist gene (IL-1RN). The IL1F10 gene is encoded by 5 exons spanning over 7.8 kb of genomic DNA, with a 1008-bp cDNA that encodes a 152-amino acid protein weighing approximately 17 kDa . IL1F10 shares between 41% and 43% amino acid identity with human IL-1 receptor antagonist (IL-1Ra) and FIL-1delta, respectively .

As a cytokine with immunomodulatory activity, IL1F10 exhibits several significant functions:

• Reduces IL22 and IL17A production by T-cells in response to heat-killed Candida albicans

• Reduces IL36G-induced production of IL8 by peripheral blood mononuclear cells

• Increases IL6 production by dendritic cells stimulated by bacterial lipopolysaccharides (LPS)

• Acts as a ligand for IL-36R/IL1RL2

IL1F10 mRNA is expressed in multiple tissues including heart, placenta, fetal liver, spleen, thymus, and tonsil, suggesting its role in various physiological processes and potential involvement in inflammatory conditions .

What are the primary applications for IL1F10 antibodies in research?

IL1F10 antibodies are versatile tools for multiple research applications:

• Western Blotting (WB): Used to detect and quantify IL1F10 protein expression in cell or tissue lysates. Most commercially available IL1F10 antibodies are validated for WB applications .

• Enzyme-Linked Immunosorbent Assay (ELISA): Enables quantitative detection of IL1F10 in biological samples such as serum, plasma, or cell culture supernatants. Both direct and indirect ELISA methodologies can be employed depending on the experimental design .

• Immunohistochemistry (IHC): Allows visualization of IL1F10 expression patterns in tissue sections, providing spatial information about protein localization and distribution .

• Immunocytochemistry (ICC): Similar to IHC but applied to cultured cells, enabling subcellular localization studies of IL1F10 .

• Functional Studies: Some antibodies may be used to neutralize IL1F10 activity in functional assays, helping researchers investigate the cytokine's role in various cellular processes .

How should researchers validate IL1F10 antibody specificity?

Validating antibody specificity is crucial for obtaining reliable research results:

• Positive and negative controls: Use samples with known IL1F10 expression (e.g., recombinant IL1F10 protein, cells transfected with IL1F10) alongside samples lacking IL1F10 expression.

• Multiple detection methods: Confirm findings using complementary techniques (e.g., WB, IHC, and ELISA) to ensure consistent results across different methodologies.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to block specific binding sites. If the antibody is specific, the signal should be significantly reduced or eliminated.

• Knockdown/knockout validation: Compare staining patterns in wild-type cells versus cells where IL1F10 has been knocked down by siRNA or knocked out using CRISPR-Cas9.

• Cross-reactivity assessment: Test the antibody against related proteins (especially other IL-1 family members that share sequence homology with IL1F10) to confirm specificity .

What tissues express IL1F10, and how should this inform experimental design?

IL1F10 mRNA is expressed in heart, placenta, fetal liver, spleen, thymus, and tonsil . This tissue expression profile should inform experimental design in several ways:

Experimental considerations:

• Select appropriate positive control tissues when validating antibodies in IHC or WB experiments

• Design cell-based assays using cell types that naturally express IL1F10 or are responsive to IL1F10 stimulation

• Consider tissue-specific expression when interpreting results from patient samples or animal models

• Account for potential variability in expression levels across different tissues when optimizing antibody dilutions and detection methods

• Include appropriate tissue-matched controls when studying IL1F10 in disease states

Researchers should also consider that expression levels may change under different physiological or pathological conditions, particularly during inflammatory responses, as IL1F10 belongs to the IL-1 cytokine family involved in immune regulation .

What are the key differences between polyclonal and monoclonal IL1F10 antibodies for research?

The choice between polyclonal and monoclonal IL1F10 antibodies depends on the research application and experimental goals:

For optimal results, researchers should consider validating experimental findings with both antibody types when possible.

How should optimal experimental conditions be determined for IL1F10 detection?

Optimization of experimental conditions is essential for successful IL1F10 detection:

For Western Blotting:

• Determine optimal antibody dilution through titration experiments (typically 1:500-1:2000 for primary antibodies)

• Test different blocking solutions (BSA vs. non-fat milk) to minimize background

• Optimize incubation times and temperatures (4°C overnight vs. room temperature for shorter periods)

• Select appropriate lysis buffers that preserve IL1F10 protein integrity

• Include both reducing and non-reducing conditions to account for potential structural epitopes

For Immunohistochemistry:

• Compare different fixation methods (formalin, paraformaldehyde, frozen sections)

• Test antigen retrieval techniques (heat-induced vs. enzymatic)

• Optimize antibody concentration and incubation parameters

• Evaluate various detection systems (HRP/DAB, fluorescence)

• Include appropriate controls (isotype control, peptide-blocked antibody)

For ELISA:

• Determine optimal coating concentration of capture antibody

• Test different blocking reagents to minimize non-specific binding

• Establish standard curves using recombinant IL1F10 protein

• Validate sample dilution ranges that fall within the linear portion of the standard curve

• Optimize detection antibody concentration and incubation conditions

Researchers should consult specific product documentation, as different antibodies may have unique optimal conditions based on their specific properties .

What are the recommended storage and handling procedures for IL1F10 antibodies?

Proper storage and handling of IL1F10 antibodies are critical for maintaining their performance over time:

Storage conditions:

• Most IL1F10 antibodies should be stored at -20°C for long-term storage or at 2-8°C for short-term use

• Some antibodies require ultra-cold storage at -80°C for maximum stability

• Always follow manufacturer-specific recommendations for each antibody product

Handling guidelines:

• Avoid repeated freeze-thaw cycles by aliquoting antibodies upon receipt

• Store working dilutions at 4°C and use within 1-2 weeks

• Protect conjugated antibodies from light exposure

• Centrifuge antibody vials briefly before opening to collect liquid at the bottom

• Use sterile techniques when handling antibodies to prevent microbial contamination

• When diluting, use recommended buffers (often PBS with carrier proteins)

• Document lot numbers and expiration dates for experimental reproducibility

Stability considerations:

• Monitor antibody performance through regular validation with positive controls

• If decreased activity is observed, prepare fresh working solutions

• Consider adding preservatives (e.g., sodium azide at 0.02%) to diluted antibodies stored at 4°C

• Follow manufacturer's recommendations for reconstitution of lyophilized antibodies

How can IL1F10 antibodies be used to study inflammatory disease mechanisms?

IL1F10 antibodies are valuable tools for investigating inflammatory disease mechanisms through multiple approaches:

Inflammatory disease research applications:

• Expression profiling: Quantify IL1F10 protein levels in patient samples versus healthy controls using ELISA or WB to identify disease-associated expression patterns.

• Tissue localization: Employ IHC to analyze the spatial distribution of IL1F10 in inflammatory lesions and compare with healthy tissues.

• Cell-specific expression: Use flow cytometry with IL1F10 antibodies to determine which immune cell populations express IL1F10 during inflammation.

• Mechanistic studies: Apply neutralizing IL1F10 antibodies in cell culture or animal models to assess functional consequences of IL1F10 blockade on inflammatory parameters.

• Correlation studies: Compare IL1F10 levels with other inflammatory mediators or clinical parameters to establish potential relationships.

Recent research has identified neutralizing autoantibodies against certain interleukins (including IL-10) in inflammatory bowel disease, suggesting a potentially similar mechanism could exist for IL1F10 . IL1F10 antibodies could help investigate whether such autoantibodies exist against IL1F10 in various inflammatory conditions and determine their functional significance.

What approaches can be used to study IL1F10 interactions with other IL-1 family members?

Understanding IL1F10's interactions with other IL-1 family members requires sophisticated experimental approaches:

• Co-immunoprecipitation (Co-IP): Use IL1F10 antibodies to pull down IL1F10 along with its binding partners, followed by immunoblotting with antibodies against other IL-1 family members to detect physical interactions.

• Proximity ligation assay (PLA): Employ pairs of antibodies (anti-IL1F10 and antibodies against other IL-1 family members) to visualize protein-protein interactions at the single-molecule level within cells.

• Competitive binding assays: Utilize labeled IL1F10 antibodies alongside unlabeled antibodies against other IL-1 family proteins to determine if they compete for binding sites.

• Functional interaction studies: Apply IL1F10 antibodies in combination with neutralizing antibodies against other IL-1 family cytokines to assess synergistic or antagonistic effects on cellular responses.

• Reporter assays: Use IL1F10 antibodies in luciferase-based reporter systems to monitor downstream signaling events following IL-1 family member stimulation.

Given IL1F10's sequence homology with IL-1Ra (41-43% identity) , researchers can explore potential shared or distinct functions between these family members using antibodies that specifically recognize each protein.

How do post-translational modifications of IL1F10 affect antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition of IL1F10:

Key considerations for PTM effects on antibody binding:

• Epitope masking: PTMs may physically obstruct antibody binding sites, reducing detection efficiency. Researchers should verify whether their antibody targets a region susceptible to modification.

• Conformational changes: Modifications can alter protein folding, affecting recognition of conformational epitopes. Using antibodies recognizing different epitopes can help overcome this limitation.

• PTM-specific antibodies: Some specialized antibodies may specifically recognize modified forms of IL1F10, enabling researchers to distinguish between modified and unmodified variants.

• Sample preparation impact: Certain sample preparation methods may alter PTM status. For example, some phosphatases in lysates may remove phosphorylation modifications unless inhibitors are included.

• Validation strategies: When studying potential PTMs on IL1F10, researchers should:

  • Compare detection using multiple antibodies recognizing different epitopes

  • Employ enzymatic treatments to remove specific modifications before antibody detection

  • Use mass spectrometry to independently confirm modification sites

While specific information about IL1F10 PTMs is limited in the provided search results, researchers investigating this area should carefully select antibodies that either target unmodified regions or specifically recognize the modifications of interest.

What are the methodological considerations for using IL1F10 antibodies in multiplex immunoassays?

Technical considerations for multiplex assays:

• Antibody compatibility: Ensure IL1F10 antibodies are compatible with multiplex platforms, considering factors such as:

  • Cross-reactivity with other analytes in the panel

  • Optimal working concentration in multiplex format

  • Buffer compatibility with other antibodies

• Assay optimization:

  • Titrate IL1F10 antibodies specifically in the multiplex context

  • Validate signal-to-noise ratios for IL1F10 detection

  • Confirm dynamic range is appropriate for expected IL1F10 concentrations

• Controls and standards:

  • Include recombinant IL1F10 standards at known concentrations

  • Test for potential matrix effects from complex biological samples

  • Incorporate spike-recovery experiments to validate detection in actual samples

• Data interpretation:

  • Account for potential antibody cross-talk in data analysis

  • Validate multiplex results with single-plex confirmation when possible

  • Consider how physiological IL1F10 levels compare to assay sensitivity limits

• Platform selection:

  • Bead-based systems (e.g., Luminex) allow higher multiplexing capacity

  • Planar arrays may offer advantages for certain applications

  • Consider throughput needs and available instrumentation when selecting platforms

Researchers should validate any new multiplex approach by comparing results to established single-analyte methods for IL1F10 detection before proceeding with large-scale studies.

How can researchers address common issues with IL1F10 detection in Western blotting?

Western blotting for IL1F10 may present several challenges. Here are solutions to common problems:

Specific recommendations:

• Use fresh samples with protease inhibitors to prevent IL1F10 degradation

• Include positive controls (recombinant IL1F10 or lysates from tissues known to express IL1F10)

• For stronger signal, consider using polyclonal antibodies which recognize multiple epitopes

• Test both reducing and non-reducing conditions to determine optimal detection

• If possible, validate results with a second IL1F10 antibody recognizing a different epitope

What strategies can optimize IL1F10 detection in immunohistochemistry?

Optimizing IL1F10 detection in immunohistochemistry requires attention to several technical aspects:

Antigen retrieval optimization:

• Compare heat-induced epitope retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

• Test different retrieval durations (10-30 minutes) to find optimal conditions

• Consider enzymatic retrieval as an alternative if heat-based methods are unsuccessful

Signal amplification techniques:

• Implement tyramide signal amplification (TSA) for enhanced sensitivity

• Use polymer-based detection systems rather than traditional ABC methods

• Consider biotin-free detection systems to eliminate endogenous biotin interference

Background reduction strategies:

• Include an endogenous peroxidase blocking step (3% H₂O₂, 10-15 minutes)

• Apply protein block with serum matching the secondary antibody host species

• Include avidin/biotin blocking when using biotin-based detection systems

• Use tissue-specific blocking reagents when working with highly autofluorescent tissues

Antibody optimization:

• Titrate primary antibody concentration (typical range: 1-10 μg/mL)

• Test extended incubation times (overnight at 4°C vs. 1-2 hours at room temperature)

• Validate antibody specificity using peptide competition controls

• Consider using monoclonal antibodies for reduced background in challenging tissues

Controls:

• Include positive control tissues (spleen, thymus, or tonsil)

• Implement proper negative controls (isotype control, secondary-only, peptide-blocked antibody)

• Compare staining patterns across multiple antibody clones when possible

How can functional neutralization of IL1F10 be validated in research assays?

Validating functional neutralization of IL1F10 requires careful experimental design:

• Dose-response testing:

  • Establish a dose-response curve using recombinant IL1F10 in a functional assay

  • Determine the minimal effective concentration of anti-IL1F10 antibody needed for neutralization

  • Document percent neutralization at different antibody:cytokine ratios

• Functional readouts:

  • Measure IL1F10-induced changes in IL6 production by dendritic cells stimulated by LPS

  • Assess IL1F10's ability to reduce IL22 and IL17A production by T-cells

  • Evaluate IL1F10's effect on IL36G-induced production of IL8

• Controls and specificity validation:

  • Include isotype control antibodies at equivalent concentrations

  • Test the neutralizing antibody against related cytokines to confirm specificity

  • Incorporate positive control neutralizing antibodies with known efficacy

• Verification methods:

  • Confirm neutralization using multiple functional readouts

  • Validate with complementary approaches (e.g., receptor blockade)

  • Test in different cell types relevant to IL1F10 biology

• Advanced validation approaches:

  • Perform competition assays with unlabeled and labeled IL1F10 antibodies

  • Use surface plasmon resonance to quantify binding kinetics and affinity

  • Conduct receptor-binding assays to confirm antibody interference with IL1F10-receptor interactions

The methodologies used to validate neutralizing autoantibodies against IL-10 in inflammatory bowel disease models could be adapted to study IL1F10 neutralization, as both are members of the interleukin family with immunomodulatory functions.

How might IL1F10 antibodies contribute to understanding autoimmune and inflammatory diseases?

IL1F10 antibodies offer significant potential for advancing our understanding of autoimmune and inflammatory diseases:

• Biomarker development:

  • IL1F10 antibodies can enable quantification of this cytokine in patient samples

  • Changes in IL1F10 levels might correlate with disease activity or treatment response

  • Standardized immunoassays could facilitate multi-center studies to establish IL1F10's biomarker potential

• Pathophysiological insights:

  • Similar to findings with anti-IL-10 autoantibodies in inflammatory bowel disease , researchers could investigate whether anti-IL1F10 autoantibodies exist in autoimmune conditions

  • IL1F10 antibodies would be essential tools for detecting such autoantibodies

  • Tissue-specific expression patterns of IL1F10 in disease states could be mapped

• Therapeutic target validation:

  • Neutralizing IL1F10 antibodies can help determine whether IL1F10 modulation might be therapeutically beneficial

  • Animal models treated with anti-IL1F10 could reveal potential outcomes of targeting this pathway in humans

  • Understanding IL1F10's role in specific disease contexts could guide therapeutic development

• Cellular mechanisms:

  • IL1F10 antibodies enable investigation of how this cytokine influences specific immune cell populations

  • Flow cytometry with IL1F10 antibodies can identify which cells produce or respond to this cytokine

  • Sequential immunoprecipitation experiments could reveal IL1F10 interaction networks

• Regulatory network analysis:

  • Given IL1F10's membership in the IL-1 family, antibodies can help position its function within broader cytokine networks

  • Multiplex analysis incorporating IL1F10 detection can provide systems-level insights into inflammatory regulation

The recent discovery of neutralizing autoantibodies against IL-10 in inflammatory bowel disease suggests similar mechanisms might exist for other immunoregulatory cytokines, making IL1F10 an intriguing candidate for investigation in this context.

What are the emerging applications of IL1F10 antibodies in single-cell analysis techniques?

Single-cell analysis technologies are revolutionizing our understanding of immune cell heterogeneity, and IL1F10 antibodies have several emerging applications in this field:

• Single-cell proteomics:

  • IL1F10 antibodies can be incorporated into mass cytometry (CyTOF) panels for high-dimensional protein analysis

  • Antibody-based tags enable IL1F10 detection in cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq)

  • Proximity extension assays using IL1F10 antibodies allow ultrasensitive detection in limited sample volumes

• Spatial proteomics:

  • IL1F10 antibodies conjugated to oligonucleotides enable spatial transcriptomics approaches

  • Multiplexed ion beam imaging (MIBI) or imaging mass cytometry (IMC) with IL1F10 antibodies can map expression in tissue contexts

  • Highly multiplexed immunofluorescence techniques can position IL1F10 within tissue microenvironments

• Functional applications:

  • IL1F10 antibodies can identify rare IL1F10-producing cells for subsequent single-cell sorting and analysis

  • Antibody-based capture of IL1F10-secreting cells enables linking of cytokine production to transcriptional states

  • Combining IL1F10 detection with activation markers allows correlation of cytokine production with cellular activation status

• Analytical considerations:

  • Optimization of antibody concentrations for single-cell applications is critical

  • Validation of specificity in high-parameter settings requires careful controls

  • Integration of protein and transcriptional data necessitates computational approaches

• Future directions:

  • Development of split-pool barcoding strategies incorporating IL1F10 antibodies

  • Integration with CRISPR screens to connect IL1F10 biology with genetic dependencies

  • Application of machine learning approaches to identify IL1F10-associated cellular states

The advancement of single-cell technologies provides unprecedented opportunities to position IL1F10 within complex cellular networks relevant to human disease.

How do animal model differences affect the selection of IL1F10 antibodies for translational research?

Species differences present important considerations when selecting IL1F10 antibodies for translational research:

• Cross-reactivity considerations:

  • Human IL1F10 antibodies may have variable cross-reactivity with murine or other species orthologs

  • The search results indicate some antibodies react with human and mouse IL1F10 , while others are human-specific

  • Researchers should explicitly verify cross-reactivity claims experimentally before proceeding with animal studies

• Sequence homology challenges:

  • Human and mouse IL1F10 proteins share approximately 70% sequence identity

  • Epitope conservation between species should be evaluated when selecting antibodies

  • For highly conserved regions, antibodies may show better cross-reactivity

• Validation requirements:

  • Each antibody should be independently validated in the species of interest

  • Positive controls from the target species should be included (e.g., recombinant mouse IL1F10 for mouse studies)

  • Negative controls using knockout tissues/cells provide definitive specificity validation

• Application-specific considerations:

  • Some applications (e.g., WB) may show better cross-reactivity than others (e.g., functional neutralization)

  • Sensitivity may differ between species even when cross-reactivity is confirmed

  • Optimal conditions may need species-specific optimization

• Translational implications:

  • When bridging preclinical to clinical studies, use antibodies validated in both human and animal samples

  • Consider developing species-specific assays in parallel for key readouts

  • Document species differences in IL1F10 biology that may affect interpretation of results